Business Context and Reporting Period
This Form 8-K Current Report was filed by Daxor Corporation (DXR) on January 18, 2022. The filing reports a corporate governance event regarding the appointment of a new member to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Caleb DesRosiers, JD, MPA, to the Board of Directors effective January 18, 2022. Mr. DesRosiers will serve until the next annual meeting, at which time he will be subject to election by shareholders.
Management Commentary and Governance Details
- Background: Mr. DesRosiers is a senior principal at Valuate Healthcare Consultancy (part of Omnicom), focusing on pharmaceutical access, managed care, and M&A. He previously served as Chief Strategy Officer at PrescribeWellness, LLC.
- Independence: The Board determined that Mr. DesRosiers meets independence standards under NYSE listing rules and Regulation S-K.
- Compensation: He will receive standard compensation for non-employee directors as described in the Proxy Statement. No special arrangements exist.
- Ownership: As of the filing date, Mr. DesRosiers holds no direct or indirect beneficial ownership in the Company's stock.
- Committees: He has not yet been appointed to any Board committee.
Key Facts for Investor Verification
- Verify the exact date of the next annual meeting to confirm the duration of Mr. DesRosiers' initial term.
- Review the Company's Proxy Statement to confirm the specific dollar amounts or structure of the "standard compensation" for non-employee directors.
- Monitor future filings for any committee assignments given to the new director.